Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$62.35

0.87 (1.42%)

, HUM

Humana

$176.61

-1.19 (-0.67%)

11:37
10/06/16
10/06
11:37
10/06/16
11:37

Duchenne muscular dystrophy parent says Sarepta drug being covered by Humana

A move into positive ground for Sarepta Therapeutics (SRPT) has coincided with the circulation of a tweet from Jenn Mcnary, who identifies herself as "fighting duchenne to save my sons" in her Twitter profile. The tweet claims that Humana Insurance (HUM) "has approved 100% coverage for a patient wanting access" to Sarepta's Exondys51. Sarepta shares, which had been in negative territory earlier in the session, have moved up 15c to $62.50 at time of writing. Reference Link

SRPT

Sarepta

$62.35

0.87 (1.42%)

HUM

Humana

$176.61

-1.19 (-0.67%)

  • 06

    Nov

SRPT Sarepta
$62.35

0.87 (1.42%)

09/28/16
09/28/16
NO CHANGE

Experts 'fairly upbeat' on Sarepta drug, says RBC Capital
After speaking with three neurologists who treat DMD, RBC Capital analyst Simos Simeonidis says that the doctors were "fairly bullish" on Sarepta's DMD treatment, EXONDYS 51. The doctors expect to use the drug "in essentially all eligible patients," according to the analyst. Simeonidis raised the price target on Sarepta to $108 from $83 and keeps an Outperform rating on the stock.
09/28/16
JMPS
09/28/16
NO CHANGE
JMPS
Street underestimating price of Sarepta drug, says JMP Securities
JMP Securities analyst Liisa Bayko expects the price of Sarepta's Exondys 51 drug will be above the company's projected annual net price of $300,000. She thinks that the price will come in "closer to $538,000 per year on a gross basis, $457,000 net of discounts and compliance." The analyst raised her price target on the shares to $90 from $60 and keeps an Outperform rating on the stock.
10/04/16
PIPR
10/04/16
NO CHANGE
Target $68
PIPR
Overweight
Piper Jaffray ups Sarepta target to $68 on Summit deal
Piper Jaffray analyst Edward Tenthoff raised his price target for Sarepta Therapeutics (SRPT) to $68 from $64 after the company licensed Summit Therapeutics' (SMMT) ezutromid to treat Duchenne Muscular Dystrophy in Europe, Turkey and the Commonwealth of Independent States. The deal is a smart way for Sarepta to capitalize on its lead in DMD with the recent FDA approval of Exondys51, Tenthoff tells investors in an intraday research note. His new price target of $68 reflects the value of ezutromid. Tenthoff reiterates an Overweight rating on Sarepta. The stock is up 1% to $61.61 in late morning trading. Summit is up 94%, or $8.17, to $16.82.
10/05/16
ADAM
10/05/16
NO CHANGE
Target $28
ADAM
Buy
Summit Therapeutics price target raised to $28 from $14 at Canaccord
Canaccord analyst Arinda Lee raised her price target on Summit Therapeutics (SMMT) to $28 from $14 following the announcement of its collaboration and licensing agreement with Sarepta Therapeutics (SRPT). The deal calls for Sarepta to gain EU commercialization rights to Summit's pipeline of oral utrophin modulators for all patients with Duchenne muscular dystrophy. Lee reiterated her Buy rating Summit Therapeutics shares.
HUM Humana
$176.61

-1.19 (-0.67%)

07/22/16
COWN
07/22/16
NO CHANGE
Target $160
COWN
Outperform
Cigna has greatest upside should DOJ block mergers, says Cowen
Cowen noted the DOJ tone toward the pending managed care deals is decidedly negative and raised the burden of proof on the companies to demonstrate the deals are not anti-competitive. Cowen believes Cigna has the most upside of the four companies involved whether the deals go through or not. Cowen has an Outperform rating and $160 price target on Cigna shares.
08/22/16
LEER
08/22/16
NO CHANGE
LEER
Leerink less positive that Anthem challenge to DOJ lawsuit will be successful
Following a conference call with an anti-trust specialist, Leerink analyst Ana Gupte is less positive that the Anthem (ANTM) challenge to the lawsuit by the DOJ will be successful. The analyst says that the specialist views the obstacles to a defense by Anthem-Cigna (CI) to the anti-trust concerns as too numerous to result in a successful close. Further, the analyst believes that any favorable decision, however unlikely, on the merger close, will likely be appealed by the DOJ. Nonetheless, the lower likelihood of this defense being successful may improve the odds of a successful Aetna (AET)-Humana (HUM) defense, the analyst notes.
08/25/16
COWN
08/25/16
NO CHANGE
COWN
Managed Care mergers unlikely to close, says Cowen
Cowen analyst Christine Arnold believes the current managed care mergers including Aetna (AET) and Humana (HUM) and Anthem (ANTM) and Cigna (CI) are unlikely to close. The analyst said the government's ability to appeal could extend the litigation process beyond the termination dates stipulated in the merger agreements. Arnold believes the Aetna/Humana merger has a better chance of closing relative to the Anthem/Cigna deal, but believes neither are likely to close.
09/22/16
EVER
09/22/16
INITIATION
EVER
Buy
Humana initiated with a Buy at Evercore ISI

TODAY'S FREE FLY STORIES

VLGEA

Village Super Market

$24.36

0.35 (1.46%)

16:25
09/25/17
09/25
16:25
09/25/17
16:25
Hot Stocks
Village Super Market CEO James Sumas to step down »

Village Super Market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNCA

Genocea

$5.33

0.04 (0.76%)

16:25
09/25/17
09/25
16:25
09/25/17
16:25
Hot Stocks
Breaking Hot Stocks news story on Genocea »

Genocea trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

AAPL

Apple

$150.55

-1.34 (-0.88%)

, DGX

Quest Diagnostics

$94.57

-7.54 (-7.38%)

16:23
09/25/17
09/25
16:23
09/25/17
16:23
General news
On The Fly: Top stock stories for Monday »

Stocks began the session…

AAPL

Apple

$150.55

-1.34 (-0.88%)

DGX

Quest Diagnostics

$94.57

-7.54 (-7.38%)

LH

LabCorp

$150.32

-4.75 (-3.06%)

TGT

Target

$58.55

-0.44 (-0.75%)

AIG

AIG

$61.01

0.3 (0.49%)

NAV

Navistar

$42.14

0.81 (1.96%)

VLKAY

Volkswagen

$33.96

-0.61 (-1.76%)

FINL

Finish Line

$10.49

0.76 (7.81%)

NE

Noble Corp.

$4.45

0.32 (7.75%)

CATM

Cardtronics

$26.10

-3.17 (-10.83%)

S

Sprint

$7.82

-0.7 (-8.22%)

SFTBF

SoftBank

$79.96

-2.7 (-3.27%)

TMUS

T-Mobile

$62.89

-1.17 (-1.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

  • 02

    Oct

  • 22

    Oct

  • 30

    Oct

  • 30

    Nov

  • 16

    May

FN

Fabrinet

$34.78

-1.17 (-3.25%)

, SANM

Sanmina

$36.00

-1.3 (-3.49%)

16:22
09/25/17
09/25
16:22
09/25/17
16:22
Hot Stocks
Fabrinet names Seamus Grady CEO »

Fabrinet (FN) announced…

FN

Fabrinet

$34.78

-1.17 (-3.25%)

SANM

Sanmina

$36.00

-1.3 (-3.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

  • 18

    Oct

  • 19

    Oct

SNX

Synnex

$116.50

0.4 (0.34%)

16:22
09/25/17
09/25
16:22
09/25/17
16:22
Hot Stocks
Breaking Hot Stocks news story on Synnex »

Synnex up 11% to $130.02…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 16

    Oct

  • 17

    Oct

GFN

General Finance Corp

$4.95

-0.1 (-1.98%)

16:21
09/25/17
09/25
16:21
09/25/17
16:21
Hot Stocks
General Finance Corp announces funding for certain acquisition »

General Finance announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEX

Kirby

$64.35

0.35 (0.55%)

16:20
09/25/17
09/25
16:20
09/25/17
16:20
Hot Stocks
Breaking Hot Stocks news story on Kirby »

Hushang Ansary reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

SNWV

Sanuwave Health

$0.14

0.015 (12.50%)

16:20
09/25/17
09/25
16:20
09/25/17
16:20
Conference/Events
Sanuwave Health to host business news update conference call »

Management provides a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PKY

Parkway

$23.00

-0.02 (-0.09%)

16:20
09/25/17
09/25
16:20
09/25/17
16:20
Hot Stocks
Parkway announces special cash dividend of $4.00 per share »

Parkway announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

CQP

Cheniere Energy Partners

$27.40

0.37 (1.37%)

16:19
09/25/17
09/25
16:19
09/25/17
16:19
Initiation
Cheniere Energy Partners initiated  »

Cheniere Energy Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHT

Red Hat

$105.76

-0.54 (-0.51%)

16:19
09/25/17
09/25
16:19
09/25/17
16:19
Hot Stocks
Red Hat reports Q1 subscription revenue up 14% in constant currency »

Subscription revenue from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

PKY

Parkway

$23.00

-0.02 (-0.09%)

16:18
09/25/17
09/25
16:18
09/25/17
16:18
Hot Stocks
Parkway says shareholders approve merger with affiliate of CPPIB »

Parkway announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

LNG

Cheniere Energy

$44.08

0.6 (1.38%)

16:18
09/25/17
09/25
16:18
09/25/17
16:18
Initiation
Cheniere Energy initiated  »

Cheniere Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHT

Red Hat

$105.76

-0.54 (-0.51%)

16:18
09/25/17
09/25
16:18
09/25/17
16:18
Earnings
Red Hat raises FY18 adjusted EPS view to $2.77-$2.79 from $2.66-$2.70 »

Consensus $2.69. Raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

RHT

Red Hat

$105.76

-0.54 (-0.51%)

16:18
09/25/17
09/25
16:18
09/25/17
16:18
Earnings
Red Hat sees Q3 adjusted EPS roughly 70c, consensus 70c »

Sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

CRAY

Cray

$18.13

-0.475 (-2.55%)

, STX

Seagate

$33.16

-0.41 (-1.22%)

16:17
09/25/17
09/25
16:17
09/25/17
16:17
Hot Stocks
Cray finishes strategic transaction of Seagate's ClusterStor business »

Cray (CRAY) announced it…

CRAY

Cray

$18.13

-0.475 (-2.55%)

STX

Seagate

$33.16

-0.41 (-1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNX

Synnex

$116.50

0.4 (0.34%)

16:17
09/25/17
09/25
16:17
09/25/17
16:17
Hot Stocks
SYNNEX raises quarterly dividend 20% to 30c per share »

The dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 16

    Oct

  • 17

    Oct

$NSD

NASDAQ Market Internals

16:17
09/25/17
09/25
16:17
09/25/17
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNX

Synnex

$116.50

0.4 (0.34%)

16:17
09/25/17
09/25
16:17
09/25/17
16:17
Earnings
SYNNEX sees Q4 adjusted EPS $2.63-$2.73, consensus $2.49 »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 16

    Oct

  • 17

    Oct

RHT

Red Hat

$105.73

-0.57 (-0.54%)

16:16
09/25/17
09/25
16:16
09/25/17
16:16
Earnings
Red Hat reports Q2 adjusted EPS 77c, consensus 67c »

Reports Q2 revenue $723M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

SNX

Synnex

$116.59

0.485 (0.42%)

16:16
09/25/17
09/25
16:16
09/25/17
16:16
Hot Stocks
Breaking Hot Stocks news story on Synnex »

SYNNEX raises quarterly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 16

    Oct

  • 17

    Oct

$NYE

NYSE Market Internals

16:16
09/25/17
09/25
16:16
09/25/17
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IVTY

Invuity

$7.80

-0.5 (-6.02%)

16:15
09/25/17
09/25
16:15
09/25/17
16:15
Hot Stocks
Invuity announces commercial launch of PhotonBlade »

Invuit announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 16

    Nov

SNX

Synnex

$116.59

0.485 (0.42%)

16:15
09/25/17
09/25
16:15
09/25/17
16:15
Earnings
Synnex reports Q3 adjusted EPS $2.16, consensus $1.97 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 16

    Oct

  • 17

    Oct

KDMN

Kadmon

$3.83

0.31 (8.81%)

16:13
09/25/17
09/25
16:13
09/25/17
16:13
Syndicate
Kadmon files to sell common stock and warrants »

Kadmon announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.